|
Gary is responsible for identifying and partnering with entrepreneurial companies focused on medical devices diagnostics specialty pharmaceuticals\drug delivery technologies and technology-related services. He also provides his operational expertise and knowledge to assist Safeguard’s existing partner companies to successfully develop launch and optimize their biopharmaceutical products and services. Joining Safeguard from BioAdvance a state initiative committed to funding early-stage life sciences companies Gary was Managing Director and Chief Operating Officer. Previously he was Chief Executive Officer at Pluvita Corporation a company developing solutions for drug and diagnostics. Gary also previously served as Chief Operating Officer at Genovo Inc. a gene therapy start-up company. He was also employed by Avigen Inc. an early-stage gene therapy company located in San Francisco as Head of Research & Development. Gary began his career with Gilead Sciences Inc. at the time a pre-IPO biotechnology company as Virology Group Leader. He received his undergraduate degree in Biological Sciences from Stanford University and received his M.D. degree and completed his medical training at Washington University and Stanford University. A board-certified internist with a hematology sub-specialty Gary has authored more that 40 research articles book chapters and reviews and is the inventor on twelve issued United States patents. Gary serves on academic and biomedical committees and boards along with the editorial board of Biotechnology Healthcare. | 